2-(2-methylbenzo[d]oxazol-5-yl)acetic acid | 38196-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-(2-methylbenzo[d]oxazol-5-yl)acetic acid
• 英文别名: (2-methyl-benzooxazol-5-yl)-acetic acid；2-Methyl-5-benzoxazolessigsaeure；2-(2-Methyl-1,3-benzoxazol-5-yl)acetic acid
• CAS: 38196-01-9
• 化学式: C₁₀H₉NO₃
• mdl: MFCD04125547
• 分子量: 191.186
• InChiKey: XZTMGHNOIGLWHW-UHFFFAOYSA-N

物化性质

• 沸点：
  358.3±17.0 °C(Predicted)
• 密度：
  1.334±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  63.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-1-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-amine 、 2-(2-methylbenzo[d]oxazol-5-yl)acetic acid 生成 (R)-2-(2-methylbenzo[d]oxazol-5-yl)-N-(1-(6-(trifluoromethyl)pyridin-3-yl)pyrrolidin-3-yl)acetamide
  参考文献：
  名称：

  USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS

  摘要：

  提供一种用于治疗或预防瘙痒的药物。用于治疗或预防瘙痒的药物中，使用具有对Cav3.2T型钙通道具有阻断作用的化合物，该化合物以一般式(I)至(VI)表示，该化合物的互变异构体、立体异构体、其药用可接受的盐或其溶剂为活性成分。

  公开号：

  EP3950059A1
• 作为产物：
  描述：

  4-羟基-3-硝基苯乙酸 在 palladium on activated charcoal 氢气 、 碳酸氢钠 作用下， 以 甲醇 为溶剂， 生成 2-(2-methylbenzo[d]oxazol-5-yl)acetic acid
  参考文献：
  名称：

  Wright,J.B., Journal of Heterocyclic Chemistry, 1972, vol. 9, p. 681 - 682

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES<br/>[FR] AMINES BICYCLIQUES SUBSTITUÉES POUR LE TRAITEMENT DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010056717A1

  公开（公告）日：2010-05-20

  Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.

  本文描述了替代的双环胺。具体来说，本文描述了作为SSTR5拮抗剂有效的替代双环胺，用于治疗、控制或预防对SSTR5拮抗有响应的疾病，如2型糖尿病、胰岛素抵抗、脂质紊乱、肥胖、动脉粥样硬化、代谢综合征、抑郁症和焦虑症。
• HIGH PENETRATION COMPOSITIONS AND USES THEREOF
  申请人：Yu Chongxi

  公开号：US20090238763A1

  公开（公告）日：2009-09-24

  The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for non-steroidal anti-inflammatory agents (NSAIAs), which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate.

  本发明涉及新型高渗透性组合物或高渗透性前药（HPP）的组成和用途，特别是用于非甾体抗炎药（NSAIAs）的HPP，其能够高效地穿过生物屏障。这里的HPP能够在穿过生物屏障后转化为父活性药物或药物代谢物，从而可以治疗与父药物或代谢物相关的疾病。此外，由于能够穿过生物屏障，这里的HPP能够到达父药物可能无法进入或无法在目标区域产生足够浓度的区域，从而提供新的治疗方法。这里的HPP可以通过各种给药途径给予受试者。例如，由于其穿透生物屏障的能力，HPP可以在局部给药到疾病作用部位并以高浓度存在，从而避免系统性给药的需要。另一个例子是，这里的HPP可以被系统性地给药到生物体内，并以更快的速率进入循环系统。
• New process for preparing 2(4-fluorophenyl) alpha methyl-5-benzoxazole acetic acid
  申请人：RAVIZZA S.p.A.

  公开号：EP0182061A1

  公开（公告）日：1986-05-28

  A process for preparing 2(4-fluorophenyl)a-methyl-5-benzoxazole acetic acid starting from 4-hydroxy-3-aminophenylacetic acid, which is firstly reacted with 4-fluorobenzoyl chloride, and the product obtained is reacted with phosphoric acid; the 2(4-fluorophenyl)5-benzoxazole acetic acid obtained in this manner is esterified with ethyl alcohol, and the ester is treated with diethyloxalate; the ethyl 2(4-fluorophenyl)5-benzoxazole oxalacetate obtained is reacted with formaldehyde and potassium carbonate to obtain ethyl 2(4-fluorophenyl)5-benzoxazole acrylate, which is hydrolysed to obtain the corresponding acid, from which the 2(4-fluorophenyl)a-methyl-5-benzoxazole acetic acid is obtained by hydrogenation.

  一种以 4-羟基-3-氨基苯乙酸为起始原料制备 2(4-氟苯基)-a-甲基-5-苯并恶唑乙酸的工艺，先将 4-羟基-3-氨基苯乙酸与 4-氟苯甲酰氯反应，得到的产物再与磷酸反应，得到的 2(4-氟苯基)-5-苯并恶唑乙酸再与乙醇酯化，酯化后的产物再与草酸二乙酯处理，得到的 2(4-氟苯基)-5-苯并恶唑草酰乙酸乙酯再与甲醛和碳酸钾反应，得到 2(4-氟苯基)-5-苯并恶唑草酰乙酸乙酯；将得到的 2(4-氟苯基)-5-苯并恶唑草酰乙酸乙酯与甲醛和碳酸钾反应，得到 2(4-氟苯基)-5-苯并恶唑丙烯酸乙酯，水解得到相应的酸，再通过氢化得到 2(4-氟苯基)-a-甲基-5-苯并恶唑乙酸。
• T-TYPE CALCIUM CHANNEL BLOCKER
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：EP3825303A1

  公开（公告）日：2021-05-26

  To provide a novel T-type calcium channel blocker. A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt of the compound, or a solvate of the compound, the tautomer, the stereoisomer, or the salt is used as a T-type calcium channel blocker. wherein A represents a phenyl which may have a substituent, a 4-membered to 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, wherein the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to a nitrogen atom of the adjacent cyclic amino by means of a carbon atom constituting these rings; B represents a phenyl which may have a substituent, a 5-membered or 6-membered heteroaryl ring composed of one to three identical or different heteroatoms selected from an oxygen atom, a sulfur atom, and a nitrogen atom and carbon atoms as ring-constituting atoms, or a heterocondensed ring composed of the heteroaryl ring and either a benzene ring or a 6-membered heteroaryl ring composed of one to two nitrogen atoms and carbon atoms, wherein the heteroaryl ring or the heterocondensed ring may have a substituent and is bonded to the adjacent cyclopropyl ring by means of a carbon atom constituting these rings; R1 and R2, which may be identical or different, each represent a hydrogen atom, a halogen atom, or the like; R3 represents a hydrogen atom, a halogen atom, or the like; n and m, which may be identical or different, each represent 0 or 1; and p represents 1 or 2.

  提供一种新型 T 型钙通道阻滞剂。 由以下通式（I）代表的化合物、该化合物的同系物或立体异构体、该化合物的药学上可接受的盐，或该化合物、同系物、立体异构体或盐的溶液可用作 T 型钙通道阻滞剂。 其中 A 代表可能具有取代基的苯基、由 1 至 3 个相同或不同的杂原子组成的 4 元至 6 元杂芳基环，这些杂原子选自氧原子、硫原子、氮原子和碳原子作为构环原子、或由杂芳基环和苯环或由一至两个氮原子和碳原子组成的 6 元杂芳基环组成的杂缩合环，其中杂芳基环或杂缩合环可具有取代基，并通过构成这些环的碳原子与相邻环状氨基的氮原子键合； B 代表可能具有取代基的苯基、由 1 至 3 个相同或不同的杂原子组成的 5 元或 6 元杂芳基环，这些杂原子选自氧原子、硫原子、氮原子和作为构环原子的碳原子、或由杂芳环和苯环或由一至两个氮原子和碳原子组成的六元杂芳环组成的杂缩合环，其中杂芳环或杂缩合环可具有取代基，并通过构成这些环的碳原子与相邻的环丙基环键合； R1 和 R2 可以相同或不同，各自代表氢原子、卤素原子或类似物； R3 代表氢原子、卤素原子或类似原子； n 和 m 可以相同或不同，各自代表 0 或 1；p 代表 1 或 2。
• SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES
  申请人：He Jiafang

  公开号：US20110207737A1

  公开（公告）日：2011-08-25

  Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.